ReviewAdvanced healthcare materials2012
Materials for diabetes therapeutics.
Review in Advanced healthcare materials, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 146 citations in OpenAlex.
- pH and Glucose Dual-Responsive Hybrid Polymeric Smart Insulin Carrier for Diabetes Treatment.Polymers · 2026Article
- Design of Nanostructured Enzyme Immobilized Platforms for Precise Diagnosis and Treatment of Endocrine Disease: An Updated Review.International journal of nanomedicine · 2026Review
- Smart Responsive Microneedles for Controlled Drug Delivery.Molecules (Basel, Switzerland) · 2023Review
- Glucose Oxidase/Egg White Protein Microparticles with a Redox Mediator for Glucose Biosensors on a Screen-Printed Electrode and a Decomposable Electrode.Biosensors · 2023Article
- Fluorescent-based biodegradable microneedle sensor array for tether-free continuous glucose monitoring with smartphone application.Science advances · 2023Article
- Characterization of Cyclic Olefin Copolymers for Insulin Reservoir in an Artificial Pancreas.Journal of functional biomaterials · 2023Article
- Microneedle Patches Loaded with Nanovesicles for Glucose Transporter-Mediated Insulin Delivery.ACS nano · 2022Article
- Comprehensive Review on Wearable Sweat-Glucose Sensors for Continuous Glucose Monitoring.Sensors (Basel, Switzerland) · 2022Review
- In Vitro Evaluation of Antibacterial, Antioxidant, and Antidiabetic Activities and Glucose Uptake through 2-NBDG by Hep-2 Liver Cancer Cells Treated with Green Synthesized Silver Nanoparticles.Oxidative medicine and cellular longevity · 2022Article
- Modulating the foreign body response of implants for diabetes treatment.Advanced drug delivery reviews · 2021Review
- Can nanoparticles and nano‒protein interactions bring a bright future for insulin delivery?Acta pharmaceutica Sinica. B · 2021Review
- Recent Advances of Biomedical Materials for Prevention of Post-ESD Esophageal Stricture.Frontiers in bioengineering and biotechnology · 2021Review
- Triggered Release of Loads from Microcapsule-in-Microcapsule Hydrogel Microcarriers: En-Route to an "Artificial Pancreas".Journal of the American Chemical Society · 2020Article
- Glucose-Responsive Microspheres as a Smart Drug Delivery System for Controlled Release of Insulin.European journal of drug metabolism and pharmacokinetics · 2020Article
- Biomaterials for stem cell engineering and biomanufacturing.Bioactive materials · 2019Review
- Glucose-Responsive Microneedle Patches for Diabetes Treatment.Journal of diabetes science and technology · 2019Review
- Evaluation of encapsulating and microporous nondegradable hydrogel scaffold designs on islet engraftment in rodent models of diabetes.Biotechnology and bioengineering · 2018Article
- Advances in bioresponsive closed-loop drug delivery systems.International journal of pharmaceutics · 2018Review
- Bioresponsive Microneedles with a Sheath Structure for HSmall (Weinheim an der Bergstrasse, Germany) · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
This review is focused on the materials and methods used to fabricate closed-loop systems for type 1 diabetes therapy. Herein, we give a brief overview of current methods used for patient care and discuss two types of possible treatments and the materials used for these therapies-(i) artificial pancreases, comprised of insulin producing cells embedded in a polymeric biomaterial, and (ii) totally synthetic pancreases formulated by integrating continuous glucose monitors with controlled insulin release through degradable polymers and glucose-responsive polymer systems. Both the artificial and the completely synthetic pancreas have two major design requirements: the device must be both biocompatible and be permeable to small molecules and proteins, such as insulin. Several polymers and fabrication methods of artificial pancreases are discussed: microencapsulation, conformal coatings, and planar sheets. We also review the two components of a completely synthetic pancreas. Several types of glucose sensing systems (including materials used for electrochemical, optical, and chemical sensing platforms) are discussed, in addition to various polymer-based release systems (including ethylene-vinyl acetate, polyanhydrides, and phenylboronic acid containing hydrogels).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.